Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity

International Journal of Cardiology

Volumn 173, Issue 3, 2014, Pages 519-521

  Ozkanlar, Yunusemre ^a   Aktas, Mustafa Sinan ^a   Turkeli, Mehmet ^b   Erturk, Nergis ^a   Oruc, Ertan ^a   Ozkanlar, Seckin ^a   Kirbas, Akin ^a   Erdemci, Burak ^b   Aksakal, Enbiya ^b  

^a ATATÜRK UNIVERSITY   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

Author keywords

Cardiotoxicity; Darbepoetin; Doxorubicin; Echocardiography; Electrocardiography; Ramipril

Indexed keywords

DOXORUBICIN; HEMOGLOBIN; INTERLEUKIN 1BETA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RAMIPRIL; TUMOR NECROSIS FACTOR ALPHA; ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ERYTHROCYTE COUNT; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOCRIT; HISTOPATHOLOGY; LEFT VENTRICULAR FRACTIONAL SHORTENING; LETTER; MALE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; HEART; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXICITY; TREATMENT OUTCOME;

ANIMALS; CARDIOTOXICITY; DOXORUBICIN; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ERYTHROPOIETIN; HEART; MALE; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84899582009     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.03.044     Document Type: Article

References (10)

1. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229
2. E. Noiri, N. Nagano, and K. Negishi et al. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats Nephron Exp Nephrol 104 2006 e6 e14
3. Y. Arbel, M. Swartzon, and D. Justo QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines Anticancer Drugs 18 2007 493 498
4. D. Silverberg, D. Wexler, M. Blum, Y. Wollman, and A. Iaina The cardio-renal anaemia syndrome: does it exist? Nephrol Dial Transplant 18 Suppl.8 2003 viii7-12
5. K.H. Kim, G.Y. Oudit, and P.H. Backx Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway J Pharmacol Exp Ther 324 2008 160 169
6. Y. Ozkanlar, Y. Nishijima, D. da Cunha, and R.L. Hamlin Acute effects of tacrolimus (FK506) on left ventricular mechanics Pharmacol Res 52 2005 307 312
7. D.P. Bicket Using ACE inhibitors appropriately Am Fam Physician 66 2002 461 468
8. J.G. Cleland, A.P. Coletta, A.L. Clark, P. Velavan, and L. Ingle Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA Eur J Heart Fail 7 2005 937 939
9. M. Feola, O. Garrone, and M. Occelli et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide Int J Cardiol 48 2011 194 198
10. A. Hiona, A.S. Lee, and J. Nagendran et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function J Thorac Cardiovasc Surg 142 2011 396 403